Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.
| Condition(s) | ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon, Coronary Slow Flow, Acute Myocardial Infarction |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention. |
| Who can participate | Inclusion Criteria: * All patients with acute STEMI undergoing primary PCI * Patients of either sex, ≥18 years of age. Exclusion Criteria: * STEMI patients with cardiogenic shock at presentation * Patients with heart block * Allergy to adenosine * Patients refuse to give consent for participation |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | National Institute of Cardiovascular Diseases, Pakistan |
| Locations | Karachi, Sindh, Pakistan; Karachi, Sindh, Pakistan |
| Start date | 2025-06-01 |
| NCT ID | NCT07536802 |
| Official listing | https://clinicaltrials.gov/study/NCT07536802 |